EVEX Hospitals joins the international hospital network on Clinerion’s Patient Network Explorer platform, bringing their patients to the attention of researchers and trial sponsors who are recruiting for clinical trials. This offers the hospitals’ patients’ earlier access to treatments and medications in Georgia.
EVEX Hospitals is the group member of Georgia Healthcare Group (GHG). GHG is the largest healthcare service provider in Georgia, with 23% market share by number of referral hospitals and community clinics beds (3,320). GHG offers a comprehensive range of inpatient and outpatient services through an integrated network of hospitals and clinics. EVEX Hospitals has a strong background in running clinical trials, with high integrity data; productive, reliable site operations; rapid country and site startup; and established ethics compliance standards across its sites.
Joining Patient Network Explorer, EVEX Hospitals’ patients and their treating physicians gain increased treatment options and access to new medical interventions. Patients will be matched to clinical studies according to their electronic health records, ensuring better screening when recruiting for clinical trials. Trial managers gain the ability to include eligible patients for trials more quickly and efficiently than before.
“We are pleased with our strong expansion in Georgia, which means we have a good representation and coverage of the country,” says Ian Rentsch, CEO of Clinerion. “This makes the services that we offer for Georgia more statistically meaningful to researchers and clinical trial managers at Pharma sponsors and CRO.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.